Clinical TrialsBiora presented a summary of BT-600 Phase 1 clinical trial data at the American College of Gastroenterology meeting, following the initial disclosure of positive results.
Product DevelopmentBiora's second primary program, Biojet, continues to make progress with the announcement of a smaller BioJet device, which increases payload capacity while decreasing its overall size.
Product PotentialKOL event highlights BT-600 Phase 1 data and reinforces NaviCap's potential in UC.
Strategic FocusBiora has disclosed a strategic realignment of its resources to focus on its BioJet program to expedite near-term results needed by Big Pharma collaborators to progress licensing and partnering discussions.